Keywords: synthelabo, gains, novastan, rights, mitsubishi, kasei, says

SYNTHELABO GAINS NOVASTAN RIGHTS

Article | 25 January 1993

Print This

Mitsubishi Kasei says it has issued licenses for the development and marketing of the antithrombin agent Novastan (argatroban) in all ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in